27.09.2014 – 09:01 Boehringer IngelheimBoehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer Ingelheim, Germany (ots/PRNewswire) - - Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20% - Head and neck cancer has a very poor prognosis with no ... more